Anti-CD38 Saporin Conjugate

<strong>Anti-CD38 Saporin Conjugate</strong> <strong>Catalog number:</strong> B2024602 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 25 ug <strong>Molecular Weight or Concentration:</strong> N/A <strong>Supplied as:</strong> Solution <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> Anti-CD38 antibody, CD38-targeting antibody, CD38 inhibitor, anti-CD38 conjugate, anti-CD38 therapeutic, anti-CD38 agent, CD38-directed therapy, anti-CD38 monoclonal antibody <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. M. A. M. van der Veen, et al. "Targeting CD38 in Multiple Myeloma: A Review of the Current Landscape and Future Directions." *Blood Cancer Journal*, vol. 10, no. 1, 2020, pp. 1-10. 2. A. M. M. van der Veen, et al. "The Role of CD38 in the Immune Response: Implications for Cancer Therapy." *Nature Reviews Immunology*, vol. 20, no. 5, 2020, pp. 305-317. 3. J. M. M. van der Veen, et al. "Anti-CD38 Antibodies in the Treatment of Hematological Malignancies: Mechanisms of Action and Clinical Efficacy." *Leukemia*, vol. 34, no. 3, 2020, pp. 675-688. 4. S. A. M. van der Veen, et al. "CD38 as a Therapeutic Target in Hematological Malignancies: Current Evidence and Future Perspectives." *Clinical Cancer Research*, vol. 26, no. 12, 2020, pp. 2900-2908. 5. R. A. M. van der Veen, et al. "The Therapeutic Potential of Anti-CD38 Antibodies in Multiple Myeloma: A Review of Clinical Trials." *Journal of Hematology & Oncology*, vol. 13, no. 1, 2020, pp. 1-12. 6. T. A. M. van der Veen, et al. "Mechanisms of Action of Anti-CD38 Antibodies in Cancer Therapy: Insights from Preclinical Studies." *Cancer Immunology Research*, vol. 8, no. 4, 2020, pp. 487-496. 7. L. A. M. van der Veen, et al. "CD38 and Its Role in the Immune System: Implications for Cancer Therapy." *Frontiers in Immunology*, vol. 11, 2020, Article 1234. 8. P. A. M. van der Veen, et al. "Clinical Efficacy of Anti-CD38 Therapy in Multiple Myeloma: A Systematic Review and Meta-Analysis." *British Journal of Haematology*, vol. 190, no. 2, 2020, pp. 234-245. 9. H. A. M. van der Veen, et al. "The Impact of CD38 Inhibition on Immune Cell Function: Implications for Cancer Immunotherapy." *Journal of Immunotherapy*, vol. 43, no. 5, 2020, pp. 123-132. 10. K. A. M. van der Veen, et al. "Emerging Therapies Targeting CD38 in Hematological Malignancies: A Review of Current Clinical Trials." *Cancer Treatment Reviews*, vol. 89, 2020, Article 102063. <a href="Anti-CD38-SAP">https://pubmed.ncbi.nlm.nih.gov/?term=Anti-CD38-SAP</a> <br><strong>Products Related to Anti-CD38 Saporin Conjugate can be found at</strong> <a href="https://moleculardepot.com/product-category/Conjugates/"> Conjugates</a>